Creating new treatments for lymphoma using immune system activation
Official title: Development of pHLIP-phosphoantigen conjugates for lymphoma therapy
Funded at University of Connecticut Storrs · NIH-10818629 · Data updated 2026-11-12
This study is testing a new treatment that helps your immune system better recognize and fight lymphoma, especially if other treatments haven't worked for you, by using a special drug that boosts certain immune cells to target cancer more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Storrs NIH-funded |
| Lab location | 1 site (Storrs-Mansfield, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $214,513 |
| NIH project number | 5R21CA273042-02 |
| Project ID | NIH-10818629 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B cell lymphoma or other lymphomas that have shown resistance to current immunotherapy treatments.
✕Less likely to help
Patients with lymphoma types that are not targeted by this research or those who have already responded well to existing immunotherapies may not benefit from this approach.
What this research studies
This research focuses on enhancing the immune system's ability to identify and eliminate cancer cells, specifically targeting lymphoma types like diffuse large B cell lymphoma. The approach involves developing a drug conjugate that activates gamma delta T cells, which are crucial for a robust immune response against tumors. By targeting a specific protein, BTN3A1, the study aims to improve the effectiveness of immunotherapy for patients who have not responded well to existing treatments. This innovative method seeks to provide a new avenue for cancer treatment by leveraging the body's own immune mechanisms.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with difficult-to-treat lymphomas.
How similar studies have gone: While the approach of targeting gamma delta T cells is promising, it is still relatively novel and has not been extensively tested in clinical settings for lymphoma treatment.
Where this research is happening
-
University of Connecticut Storrs
Storrs-Mansfield, United States Active
Researchers
- Principal investigator: Wiemer, Andrew J — University of Connecticut Storrs
- Study coordinator: Wiemer, Andrew J
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Preventing follicular lymphoma progression with precision therapy
This grant tests a targeted approach to stop follicular lymphoma from getting worse or turning into a more aggressive cancer.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Cyclin D1 and DNA Repair in Mantle Cell Lymphoma: A Path to New Therapies
A clinician-researcher at Mayo Clinic is pursuing advanced training and research to understand how Cyclin D1 drives replication stress and to explore new targeted treatments for high-risk mantle cell lymphoma.
-
Targeting the IL-1R Pathway to Boost Immunotherapy for Anaplastic Large Cell Lymphoma
Aims to make CD30 CAR therapies work better for people with ALCL by blocking a immune-evasion pathway.
-
Radiation Therapy Innovation to Improve Lymphoma Trials and Carbon Ion Research Path
A Mayo Clinic-led effort to better design and run lymphoma trials by integrating advanced radiation therapy and exploring carbon ion radiotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.